IGF-1 LR3 (1mg)
IGF-1 LR3 (Long Arg³ Insulin-like Growth Factor-1) is a modified form of insulin-like growth factor-1 with extended half-life, investigated in research for its effects on muscle protein synthesis, cellular growth, and tissue repair.
About IGF-1 LR3
IGF-1 LR3 (Long Arg³ IGF-1) is a modified version of human IGF-1 with two key structural changes: an arginine substituted for glutamic acid at position 3, and a 13-amino-acid extension at the N-terminus. These modifications reduce binding affinity for IGF-binding proteins, substantially extending the compound’s circulating half-life relative to native IGF-1.
Mechanism in Research Literature
Research on IGF-1 LR3 has documented:
- Binding to IGF-1 receptors with comparable affinity to native IGF-1
- Reduced binding to IGF-binding proteins (IGFBPs), extending half-life from minutes to ~20-30 hours
- Stimulation of muscle protein synthesis in research models
- Activation of satellite cells and downstream anabolic signaling
- Effects on cellular proliferation in multiple tissue types
- Mediation of many of the anabolic effects classically attributed to growth hormone
Research Context
IGF-1 LR3 has been investigated in studies exploring:
- Muscle protein synthesis and hypertrophy research
- Comparative pharmacokinetics vs. native IGF-1
- Downstream effects of GH-pathway signaling
- Cellular proliferation and tissue regeneration
- Body composition research in metabolic models
Related Research Peptides
IGF-1 LR3 appears in literature alongside upstream GH-releasing peptides (CJC-1295, Ipamorelin, Sermorelin, Tesamorelin) and tissue-repair compounds (BPC-157, TB-500).
